On March 31, 2017 Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, reported key presentations of clinical and scientific data related to its products at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting being held in Washington, D.C., from April 1-5, 2017 (Press release, Spectrum Pharmaceuticals, MAR 31, 2017, View Source [SID1234518393]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The following ROLONTIS (eflapegrastim) related abstract is being presented at the AACR (Free AACR Whitepaper) meeting:

Monday, April 3, 2017:

Abstract # Type Title First Author Time
1347 Poster In vivo efficacy of eflapegrastim in rats with chemotherapy-induced neutropenia Kim 8:00 AM -12:00 PM

The following key BELEODAQ (belinostat) for injection related abstracts are being presented at the AACR (Free AACR Whitepaper) meeting:

Monday, April 3, 2017:

Abstract # Type Title First Author Time
1059 Poster Enhanced anti-tumor efficacy of a checkpoint inhibitor in combination with the HDAC inhibitor belinostat in a murine hepato-cellular carcinoma preclinical model Llopiz 8:00 AM-12:00 PM

2018 Poster Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin’s lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms Nguyen 1:00 PM-5:00 PM

For more information about the AACR (Free AACR Whitepaper) meeting and for a complete list of abstracts, please refer to the conference website at View Source!/4292.